Davini A, Cellerini F, Topi P L
U.O. Malattie Cardiovascolari, USL n. 16 Val d'Era, Pontedera, Pisa.
Minerva Cardioangiol. 1992 Nov;40(11):449-53.
Coenzyme Q10, a mitoquinone involved in mitochondrial energy synthesis and the removal of free radicals, may be lacking in a number of cardiac pathologies leading to reduced contractile activity. The administration of exogenous coenzyme Q10 may help to improve contractile activity. In order to assess this hypothesis 63 patients suffering from altered myocardial contractile function (29 dilated cardiopathies, 15 valvular cardiopathies, 19 ischemic cardiopathies) which presented a NYHA class above 2 were selected. The study was open and patients were subdivided into two groups, one of which received conventional therapy alone whereas the other also received exogenous coenzyme Q10. After 4 months of follow-up clinical (NYHA class, effort tolerance) and echocardiographical (ventricular diameter and contraction fraction %) parameters were evaluated. In those patients treated with coenzyme Q10 and suffering from dilated cardiomyopathy a significant reduction in the NYHA class and a marked improvement in echocardiographic parameters were observed at the end of this period. The variations observed in other groups of patients treated were less conspicuous and not always statistically significant. The results of this study confirm that the association of coenzyme Q10 and conventional therapy may lad to a marked improvement in contractile function and correlated clinical conditions.
辅酶Q10是一种参与线粒体能量合成及清除自由基的线粒体醌，在许多导致收缩活性降低的心脏疾病中可能缺乏。给予外源性辅酶Q10可能有助于改善收缩活性。为了评估这一假设，选择了63例心肌收缩功能改变的患者（29例扩张型心肌病、15例瓣膜性心脏病、19例缺血性心脏病），其纽约心脏协会（NYHA）心功能分级高于2级。该研究为开放性研究，患者被分为两组，其中一组仅接受传统治疗，而另一组还接受外源性辅酶Q10。在随访4个月后，评估临床（NYHA分级、运动耐力）和超声心动图（心室直径和收缩分数%）参数。在接受辅酶Q10治疗的扩张型心肌病患者中，在此期间结束时观察到NYHA分级显著降低，超声心动图参数明显改善。在其他接受治疗的患者组中观察到的变化不太明显，且并非总是具有统计学意义。本研究结果证实，辅酶Q10与传统治疗联合应用可能会使收缩功能及相关临床状况显著改善。
